{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Rhabdoid+Tumor&page=2", "query": { "condition": "Refractory Rhabdoid Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Rhabdoid+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T21:35:52.852Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03709680", "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ewing Sarcoma", "Solid Tumors", "Rhabdoid Tumor", "Rhabdomyosarcoma", "Neuroblastoma", "Medulloblastoma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 128, "start_date": "2019-05-24", "completion_date": "2025-10-18", "has_results": false, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709680" }, { "nct_id": "NCT04416568", "title": "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Rhabdoid Tumor", "Rhabdoid Tumor of the Kidney", "Epithelioid Sarcoma", "Chordoma (Poorly Differentiated or De-differentiated)", "Atypical Teratoid/Rhabdoid Tumor", "Other INI1 Negative Tumors (With PI Approval)", "Other SMARCA4-deficient Malignant Tumors (With PI Approval)" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "6 Months to 40 Years" }, "enrollment_count": 45, "start_date": "2020-08-14", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 8, "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416568" }, { "nct_id": "NCT04284774", "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Recurrent Adrenal Gland Pheochromocytoma", "Recurrent Ectomesenchymoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdoid Tumor of the Kidney", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Thyroid Gland Carcinoma", "Recurrent WHO Grade 2 Glioma", "Refractory Adrenal Gland Pheochromocytoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdoid Tumor of the Kidney", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Thyroid Gland Carcinoma", "Refractory WHO Grade 2 Glioma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 5, "start_date": "2020-10-13", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 171, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284774" }, { "nct_id": "NCT00326664", "title": "AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Cerebral Anaplastic Astrocytoma", "Childhood Cerebral Astrocytoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood Infratentorial Ependymoma", "Childhood Oligodendroglioma", "Childhood Spinal Cord Neoplasm", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Neoplasm", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway Glioma" ], "interventions": [ { "name": "Cediranib Maleate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 55, "start_date": "2006-03", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-03-07", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 11, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00326664" }, { "nct_id": "NCT03213652", "title": "Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Malignant Solid Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 13, "start_date": "2018-04-17", "completion_date": "2026-10-03", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 122, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213652" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT02390843", "title": "Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Retinoblastoma", "Clear Cell Sarcoma", "Renal Cell Carcinoma", "Rhabdoid Tumor", "Wilms Tumor", "Hepatoblastoma", "Neuroblastoma", "Germ Cell Tumors", "Ewings Sarcoma", "Non-rhabdomyosarcoma Soft Tissue Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Simvastatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Myeloid growth factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "29 Years", "sex": "ALL", "summary": "1 Year to 29 Years" }, "enrollment_count": 13, "start_date": "2015-02", "completion_date": "2019-09-22", "has_results": false, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02390843" }, { "nct_id": "NCT00089245", "title": "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "Iodine I 131 MOAB 8H9", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 177, "start_date": "2004-02-05", "completion_date": "2022-02-02", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089245" }, { "nct_id": "NCT02444546", "title": "Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Astrocytoma", "Childhood Atypical Teratoid/Rhabdoid Tumor", "Diffuse Intrinsic Pontine Glioma", "Glioma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Medulloblastoma", "Recurrent Primitive Neuroectodermal Tumor", "Refractory Brain Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Wild-type Reovirus", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "10 Years to 21 Years" }, "enrollment_count": 6, "start_date": "2015-06-21", "completion_date": "2022-11-21", "has_results": false, "last_update_posted_date": "2023-04-24", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02444546" }, { "nct_id": "NCT05985161", "title": "A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wilms Tumor", "Rhabdoid Tumor", "Malignant Peripheral Nerve Sheath Tumors", "MPNST", "Nephroblastoma", "XPO1 Gene Mutation", "Solid Tumor" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 45, "start_date": "2023-08-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-05-21T21:35:52.852Z", "location_count": 16, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05985161" } ] }